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ENHANCED URINARY ANGIOTENSINOGEN EXCRETION IN
CYP1A1-REN2 TRANSGENIC RATS WITH INDUCIBLE ANG II-
DEPENDENT MALIGNANT HYPERTENSION
Carlo J. Milani, Hiroyuki Kobori, John J. Mullins, and Kenneth D. Mitchell
Department of Physiology, Hypertension and Renal Center of Excellence, Tulane University Health
Sciences Center, New Orleans, Louisiana; and Center for Cardiovascular Science, University of
Edinburgh Medical School, Edinburgh, Scotland
Abstract
Background—Previous studies have demonstrated that the urinary excretion of angiotensinogen
is significantly increased in ANG II-infused hypertensive rats, which is associated with an
augmentation of intrarenal ANG II levels. These findings suggest that urinary angiotensinogen
excretion rates provide an index of intrarenal ANG II levels in ANG II-dependent hypertensive states.
However, little information is available regarding the urinary excretion of angiotensinogen in ANG
II-dependent malignant hypertension.
Methods—The present study was performed to determine if urinary angiotensinogen excretion is
increased in Cyp1a1-Ren2 transgenic rats [strain name: TGR(Cyp1aRen2)] with inducible ANG II-
dependent malignant hypertension. Adult male Cyp1a1-Ren2 rats (n=6) were fed a normal diet
containing 0.3% indole-3-carbinol (I3C) for 10 days to induce ANG II-dependent malignant
hypertension.
Results—Rats induced with I3C exhibited pronounced increases in systolic blood pressure (SBP)
(208±7 vs. 127±3 mmHg, P<0.001), marked proteinuria (29.4±3.6 vs. 5.9±0.3 mg/day, P<0.001),
and augmented urinary angiotensinogen excretion (996±186 vs. 241±31 ng/day, P<0.01). Chronic
administration of the AT1 receptor antagonist, candesartan (25 mg/L in drinking water, n=6),
prevented the I3C-induced increases in SBP (125±5, P<0.001), proteinuria (7.3±1.0 mg/day,
p<0.001) and urinary angiotensinogen excretion (488±51 ng/day, P<0.01).
Conclusions—These data demonstrate that the urinary excretion of angiotensinogen is markedly
augmented in ANG II-dependent malignant hypertension. Such increased urinary angiotensinogen
excretion may contribute to augmented intrarenal ANG II levels and, thereby, to the increased blood
pressure in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension.
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kidney; renin-angiotensin system; malignant hypertension; proteinuria; blood pressure;
angiotensinogen
Address correspondence to: Kenneth D. Mitchell, PhD, FAHA, FASN, Department of Physiology, Tulane University Health Sciences
Center, 1430 Tulane Avenue, SL39, New Orleans, LA 70112, Phone: 504-988-2593, Fax: 504-988-2675, kdmitch@tulane.edu.
Address for reprint requests and other correspondence: Kenneth D. Mitchell, PhD, FAHA, FASN, Department of Physiology,
Hypertension and Renal Center of Excellence, Tulane University Health Sciences Center, 1430 Tulane Avenue, SL39, New Orleans, LA
70112. kdmitch@tulane.edu
NIH Public Access
Author Manuscript
Am J Med Sci. Author manuscript; available in PMC 2011 November 1.
Published in final edited form as:
Am J Med Sci. 2010 November ; 340(5): 389–394. doi:10.1097/MAJ.0b013e3181eabd28.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Introduction
Previous studies have demonstrated that kidney ANG II contents of 2K1C Goldblatt
hypertensive rats, ANG II-infused hypertensive rats, TGR(mRen2)27 transgenic rats, and
hypertensive Cyp1a1-Ren2 transgenic rats are markedly higher than can be explained on the
basis of circulating ANG II concentrations even though the kidneys are exposed to markedly
elevated arterial blood pressures.1–5 This augmentation of total kidney ANG II content may
occur secondary to AT1 receptor-mediated uptake of circulating ANG II and/or AT1 receptor-
mediated stimulation of intrarenal angiotensinogen and ANG II generation.6–8 Indeed, it has
been demonstrated that ANG II-infusion in normal rats results in paradoxical increases in renal
expression of angiotensinogen mRNA and protein.8–10 In addition, the urinary excretion of
angiotensinogen is significantly increased in ANG II-infused hypertensive rats, which is
associated with an augmentation of intrarenal ANG II levels.8,11,12 These findings suggest that
urinary angiotensinogen excretion rates provide an index of intrarenal ANG II levels in ANG
II-dependent hypertensive states. However, little information is available regarding the urinary
excretion of angiotensinogen in ANG II-dependent malignant hypertension.
Malignant hypertension is a severe form of hypertension characterized by rapidly increasing
blood pressure, pressure diuresis and natriuresis, severe renal vasoconstriction and ischemia,
activation of the renin-angiotensin system, microangiopathy, hemolytic anemia, and
development of retinopathy.5,13–16 The vascular lesions of malignant hypertension in the
kidney consist of myointimal proliferation and fibrinoid necrosis.13–16 A transgenic rat line
[strain name TGR(Cyp1a1Ren2)] was created that allows the induction of various degrees of
ANG II-dependent hypertension.16 This transgenic rat line was generated by inserting the
mouse Ren2 renin gene, fused to an 11.5-kb fragment of the cytochrome P-450 1a1 (Cyp1a1)
promoter, into the genome of the Fischer 344 rat.16 Cyp1a1, which catalyzes the oxidation of
a wide range of endogenous lipophilic compounds and xenobiotics17–19, is not constitutively
expressed. However, Cyp1a1 is highly inducible on exposure to various aryl hydrocarbons
such as indole-3-carbinol (I3C).17–23 Induction of Cyp1a1 is mediated by the aryl hydrocarbon
receptor, which is a basic helix-loop-helix transcription factor that binds to specific DNA
elements in the Cyp1a1 promoter.17,19,24 Rats transgenic for the Cyp1a1-Ren2 construct do
not constitutively express the Ren2 renin gene. The Ren2 gene is expressed, primarily in the
liver, only after induction of the Cyp1a1 promoter by aryl hydrocarbons such as I3C.16
Essentially, induction of the Cyp1a1 promoter by I3C is used to drive hepatic expression of
the Ren2 renin gene. In this transgenic rat model, induction of the Cyp1a1 promoter by dietary
administration of I3C results in a fixed level of expression of the Ren2 renin gene and in the
development of ANG II-dependent hypertension.5,16,25 At a dose of 0.3% (wt/wt), dietary I3C
induces malignant hypertension, characterized by loss of body weight, polyuria, polydipsia,
lethargy, and piloerection. Therefore, this model allows the induction of ANG II-dependent
malignant hypertension using a benign and naturally occurring dietary supplement without the
need for surgical intervention, dietary salt manipulation, or the administration of steroids.
The present study was performed to determine if urinary angiotensinogen excretion is increased
in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension. In
light of the evidence that increased urinary angiotensinogen excretion in ANG II-dependent
hypertensive states occurs in part as a consequence of AT1 receptor mediated stimulation of
proximal tubular angiotensinogen production8, an additional objective was to determine the
effects of chronic AT1 receptor blockade on the urinary excretion of angiotensinogen in
Cyp1a1-Ren2 rats with malignant hypertension.
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Methods
The experimental procedures in this study conform to the National Institutes of Health Guide
for the Care and Use of Laboratory Animals and were approved by the Institutional Animal
Care and Use Committee of Tulane University Health Sciences Center. Experiments were
performed on adult male transgenic rats [TGR(Cyp1a1Ren2)] with inducible expression of the
mouse Ren2 renin gene.16 All transgenic rats used in the present study were bred at Tulane
University School of Medicine from stock animals supplied by Harlan UK Limited, Bicester,
UK. The experimental animals were divided into three groups. Group 1 (Non-induced; n=6)
Cyp1a1-Ren2 rats were maintained on a normal rat diet (diet TD 99414, Harlan-Teklad,
Madison, WI). Group 2 (0.3% I3C; n=6) Cyp1a1-Ren2 rats were fed a normal diet containing
a I3C at a dose of 0.3% (wt/wt; diet TD 05381, Harlan-Teklad) for 10 days to induce ANG II-
dependent malignant hypertension, as described previously.5,26–29 Group 3 (0.3% I3C+Cand;
n=6) rats were fed 0.3% I3C and treated chronically with the AT1 receptor blocker candesartan
(AstraZeneca UK Ltd., Macclesfield, Cheshire, UK) for 10 days. Candesartan was added to
the drinking water at a concentration of 25 mg/L. We have previously demonstrated that this
dose of candesartan prevents the development of malignant hypertension in Cyp1a1-Ren2
transgenic rats.5
Measurement of systolic blood pressure was obtained in conscious rats using computerized
tail-cuff plethysmography (Model 6R22931, IITC Instruments; Woodland Hills, CA). All rats
were trained for two weeks prior to the beginning of the experiment in order to habituate them
to this procedure. Blood pressures were measured every day throughout the duration of the
study. Body weight was similarly measured every day throughout the course of the study. Rats
were placed in metabolic cages and twenty-four hour urine collections were obtained on days
−6, −3, 2, 4, and 10 relative to initiating dietary I3C administration for determination of 24-hr
urinary angiotensinogen and protein excretion. Urine samples were centrifuged and the
supernatant separated and stored at −20°C until assayed for protein or stored at −80°C until
assayed for angiotensinogen concentrations. Urine volume was determined gravimetrically.
Urine protein concentrations were measured by a colorimetric assay using a commercially
available kit (Bio-Rad). Urinary angiotensinogen concentrations were determined using a
rodent angiotensinogen sandwich ELISA as described previously.30
Statistical analyses were performed using one-way repeated measures ANOVA followed by
Student -Newman-Keuls test for within group analyses, and one-way and two-way repeated
measures ANOVA followed by Student-Newman-Keuls test for between group analyses. All
statistical analyses were performed using SigmaPlot for Windows (version 11, Systat Software
Inc., San Jose, CA). Statistical significance was defined as P < 0.05. All data are expressed as
mean ± SE.
Results
The effects of dietary administration of I3C and I3C+Cand on conscious systolic blood pressure
of Cyp1a1-Ren2 transgenic rats are summarized in Fig. 1. Chronic administration of 0.3% I3C
for 10 days resulted in the development of severe hypertension, with blood pressure increasing
from 127±3 to 208±7 mmHg (P<0.001) over the 10 day period of I3C induction. As shown in
Fig. 1, chronic administration of candesartan completely prevented the I3C-induced increase
in SBP (126±4 vs. 125±5 mmHg) confirming our previous observations that the I3C-induced
increase in SBP is mediated via activation of AT1 receptors by ANG II generated as a
consequence of expression of the Cyp1a1-Ren2 transgene. SBP in the non-induced control rats
similarly remained unaltered from day 0 to day 8, but increased by day 10 (151±5 vs. 128±2
mmHg, P<0.001). As shown in Fig. 2, the development of hypertension was associated with
a pronounced reduction in body weight from 206±6 to 146±5 g (P<0.001). In addition, the
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hypertensive rats demonstrated severe lethargy, assumption of a hunched posture, and
piloerection, which are manifestations of malignant hypertension in the rat.5,13–16,26–29 In
contrast, the rats induced with I3C+Cand exhibited a small but significant increase in body
weight over the 10 day induction period (195±3 to 210±3 g, P<0.001) (Fig. 2). Body weight
in the non-induced rats remained unaltered (212±5 vs. 224±11 g) over the 10 day measurement
period.
The effects of I3C and I3C+Cand on urinary protein excretion in Cyp1a1-Ren2 rats are shown
in Fig. 3. Dietary administration of I3C increased protein excretion from 5.9±0.3 to 29.4±3.6
mg/day (P<0.001) over the 10 days of I3C administration. As shown in Fig. 3, chronic
administration of candesartan prevented the I3C-induced increase in urinary protein excretion
(5.2±0.5 vs. 7.3±1.0 mg/day). Protein excretion in the non-induced rats remained unaltered
(7.6±0.6 vs. 6.3±0.8 mg/day) throughout the 10 day measurement period. Fig. 4. shows the
effects of I3C and I3C+Cand on urinary angiotensinogen excretion in Cyp1a1-Ren2 rats.
Urinary angiotensinogen excretion was significantly elevated on day two of I3C induction (743
±124 vs. 241±31 ng/day, P<0.05) and increased further to 1298±325 ng/day (P<0.001) by day
4. Urinary angiotensinogen remained substantially elevated on day 10 (996±186 ng/day,
P<0.01). As shown in Fig. 4, chronic administration of candesartan markedly attenuated the
I3C-induced increase in urinary angiotensinogen excretion with urinary angiotensinogen
excretion increasing from 216±14 to 488±51 ng/day (P<0.001) in the rats induced with I3C
and treated chronically with candesartan. Urinary angiotensinogen excretion was markedly
lower in rats induced with I3C and treated with candesartan at all time points (P<0.001)
compared with corresponding values in rats induced with I3C alone (Fig. 4.). Urinary
angiotensinogen excretion in the non-induced control rats remained unaltered (225±60 vs. 217
±39 ng/day) throughout the course of the experiment.
Discussion
The present study was performed to determine if urinary angiotensinogen excretion is increased
in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension.
Malignant hypertension is a form of severe hypertension characterized by fibrinoid necrosis
of arterioles and vascular damage in many tissues, including the kidney.13–16,28 The Cyp1a1-
Ren2 transgenic line allows the induction of ANG II-dependent malignant hypertension.5,16,
25–29 This transgenic line was generated by inserting a mouse Ren2 renin gene into the genome
of the Fischer 344 rat.16 Extrarenal Ren2 renin gene expression is induced by the administration
of the aryl hydrocarbon I3C, resulting in the development of ANG II-dependent malignant
hypertension.5,16,25–29 Such induction of Ren2 renin gene expression using a benign and
naturally occurring dietary supplement leads to the development of ANG II-dependent
hypertension as a result of increased renin gene expression and plasma renin levels, which are
not subject to normal physiological feedback control mechanisms. In the present study,
induction of the Ren2 renin gene by dietary administration of 0.3% I3C for 10 days resulted
in the development of severe hypertension. As described previously5,16,26–29, the hypertension
was associated with a marked decrease in body weight, and the rats exhibited extreme lethargy,
assumption of a hunched posture, and piloerection, which are clinical manifestations of
malignant hypertension in the rat.5,13–16 The development of malignant hypertension was
associated with pronounced increases in the urinary excretion of angiotensinogen.
The development of malignant hypertension in Cyp1a1-Ren2 rats was also associated with
increased urinary protein excretion. Thus, it is possible that the increased urinary
angiotensinogen excretion occurred as a consequence of the nonspecific effects of the
hypertension or of the enhanced urinary excretion of protein. In essence, it is possible that
glomerular filtration of angiotensinogen into the tubular fluid, driven by high intraglomerular
pressure and glomerular damage, contributed to the observed increase in urinary
Milani et al. Page 4
Am J Med Sci. Author manuscript; available in PMC 2011 November 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
angiotensinogen excretion. However, previous studies performed in DOCA-salt hypertensive
rats demonstrated urinary protein excretion in DOCA-salt hypertensive rats was significantly
higher than in ANG II-infused hypertensive rats.12 In contrast, urinary excretion of
angiotensinogen was significantly lower in DOCA-salt hypertensive rats than in ANG II-
infused hypertensive rats indicating dissociation between urinary protein excretion and the
urinary angiotensinogen excretion rate.12 However, we have demonstrated that renal cortical
angiotensinogen mRNA expression in Cyp1a1-Ren2 transgenic rats with malignant
hypertension is not different from that observed in normotensive control rats.31 These findings
suggest that increased glomerular filtration of angiotensinogen contributed substantially to the
observed increase in urinary angiotensinogen excretion in Cyp1a1-Ren2 rats with malignant
hypertension. Nevertheless, one cannot rule out the possibility that ANG II-induced proximal
tubular secretion of angiotensinogen contributed, in part, to the observed increase in urinary
angiotensinogen excretion in Cyp1a1-Ren2 rats with malignant hypertension. Further studies
are required to address this issue.
The observation that urinary protein excretion, a parameter of renal injury, was markedly
increased in the hypertensive rats is consistent with our previous observations that the kidneys
of Cyp1a1-Ren2 rats with malignant hypertension exhibit glomerulosclerosis, myointimal
hyperplasia and tubular dilation, and tubulointerstitial inflammation and proliferation,
particularly in the perivascular areas.28 Collectively, these findings indicate that Cyp1a1-Ren2
rats with malignant hypertension exhibit pronounced renal injury. In the present study, chronic
blockade of AT1 receptors with candesartan completely prevented the I3C-induced increase
in proteinuria indicating that AT1 receptor activation by ANG II is responsible for the
development of proteinuria and the associated renal injury in Cyp1a1-Ren2 rats with malignant
hypertension. However, the present data do not allow determination of the degree to which the
prevention of the proteinuria by candesartan occurred as a consequence of blockade of the
direct blood pressure-independent renal actions of AT1 receptor activation by ANG II or was
due to the associated prevention of the hypertension. Additional studies are required to address
this issue.
It has been demonstrated that kidney ANG II contents of 2K1C Goldblatt hypertensive rats,
ANG II-infused hypertensive rats, TGR(mRen2)27 transgenic rats, and hypertensive Cyp1a1-
Ren2 transgenic rats are substantially higher than the prevailing circulating ANG II
concentrations even though the kidneys are exposed to markedly elevated arterial blood
pressures.1–5 In the present study, the rats with malignant hypertension exhibited substantially
elevated urinary angiotensinogen excretion rates compared with non-induced controls. This
observation is consistent with previous observations that the urinary excretion of
angiotensinogen is significantly increased in ANG II-infused hypertensive rats, which is
associated with an augmentation of intrarenal ANG II levels.8,11,12 The present finding that
urinary angiotensinogen excretion is increased in Cyp1a1-Ren2 rats with malignant
hypertension together with our previous observations that the pathogenesis of ANG II-
dependent malignant hypertension in Cyp1a1-Ren2 transgenic rats involves augmentation of
plasma and total kidney ANG II levels5,27 indicates that Cyp1a1-Ren2 rats with malignant
hypertension exhibit a paradoxical increase in the activity of the intrarenal renin-angiotensin
system. Chronic blockade of AT1 receptors with candesartan markedly attenuated the I3C-
mediated augmentation of urinary angiotensinogen excretion indicating that the elevated
urinary angiotensinogen excretion in the rats with malignant hypertension was dependent on
activation of AT1 receptors. In this regard, it is possible that the augmentation of urinary
angiotensinogen excretion in the rats with malignant hypertension may have occurred, in part,
to AT1 receptor-mediated stimulation of angiotensinogen secretion by the proximal tubules,
such as occurs in ANG II-infused hypertensive rats.8 It is also possible that other mechanisms
such as oxidative stress may have contributed to the increased urinary angiotensinogen
excretion in the hypertensive Cyp1a1-Ren2 rats. Indeed, we have previously demonstrated that
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Cyp1a1-Ren2 transgenic rats with malignant hypertension exhibit elevated basal rates of
urinary excretion of 8-isoprostane indicating oxidative stress in this model of ANG II-
dependent malignant hypertension.29 In addition, administration of the AT1 receptor
antagonist, candesartan, significantly decreased the urinary excretion of 8-isoprostane,
indicating that ANG II stimulates the production of superoxide anion in Cyp1a1-Ren2 rats with
malignant hypertension.29 Such ANG II-mediated increase in superoxide anion levels may
contribute to the increase in urinary angiotensinogen excretion in hypertensive Cyp1a1-Ren2
rats.
The increased urinary angiotensinogen excretion indicates that greater amounts of
angiotensinogen, either filtered at the glomerulus or secreted into the tubular fluid by the
proximal tubule cells, traverse the distal nephron segments and may result in increased
generation of ANG II in distal tubular fluid as well as proximal tubular fluid.8 In this regard,
we have recently demonstrated that renin immunoreactivity in the JG cells is not suppressed
and that collecting duct renin immunoreactivity is markedly increased in kidneys of Cyp1a1-
Ren2 transgenic rats with malignant hypertension.32 Similarly, kidney cortex renin content in
hypertensive Cyp1a1-Ren2 rats is significantly elevated compared with normotensive control
rats.31 These recent findings are in contrast to the previous observation that rat renin and mRen2
renin expression are absent in the kidneys of Cyp1a1-Ren2 rats with malignant hypertension.
16 The reason for this apparent discrepancy is not clear; however, it has been demonstrated that
collecting duct renin is enhanced in the non-clipped kidneys of 2K1C Goldblatt hypertensive
rats and in the kidneys of ANG II infused hypertensive rats despite the fact that these kidneys
are exposed to markedly elevated arterial blood pressures.33 The mechanisms responsible for
the increased collecting duct renin in ANG II-dependent hypertensive states remain unclear.
However, it is possible that a local amplification mechanism exists whereby intrarenal ANG
II stimulates collecting duct renin synthesis and secretion into the cortical and medullary
collecting duct fluid. Such increased cortical and medullary collecting duct renin levels
together with elevated intratubular angiotensinogen levels may result in increased intratubular
ANG II generation and, thereby, allow moderate increases in intrarenal ANG II levels to further
augment intratubular ANG II levels.33 Regardless of the specific mechanisms involved, our
previous observation that renin immunoreactivity in the JG cells is not suppressed and that
collecting duct renin immunoreactivity is markedly increased in kidneys of hypertensive
Cyp1a1-Ren2 transgenic rats indicates that the kidneys of Cyp1a1-Ren2 rats with malignant
hypertension are not renin-depleted. The maintained JG cell and augmented collecting duct
renin together with the enhanced tubular fluid angiotensinogen levels may contribute to
augmented intratubular ANG II levels. Such increased tubular fluid ANG II generation may
account, at least in part, for the elevated intrarenal ANG II levels observed in Cyp1a1-Ren2
transgenic rats with ANG II-dependent malignant hypertension.5 It is also possible that, in
addition to increased intratubular generation of ANG II, the elevated intrarenal ANG II levels
observed in hypertensive Cyp1a1-Ren2 rats occurred, in part, as a consequence of uptake of
the peptide via AT1 receptor sequestration. Thus, increased kidney ANG II content may result
from the combination of uptake of circulating ANG II and local formation of ANG II from
enhanced intraluminal angiotensinogen levels. Whatever the mechanism, to the extent that
AT1 receptors are located on both the luminal and basolateral membranes of the proximal
tubule as well as in the distal nephron segments and collecting ducts34 it is likely that increases
in intrarenal ANG II levels would act to increase proximal and distal nephron sodium chloride
and fluid reabsorption rate. Such renal tubular actions of the inappropriately elevated intrarenal
ANG II levels would contribute to an impaired ability of the kidney to maintain normal rates
of sodium excretion except at hypertensive arterial pressures, and impair the pressure
natriuretic response to the ANG II-mediated increases in arterial blood pressure.5,35 In this
manner, by maintaining an inappropriately high reabsorptive status and an impaired pressure
natriuresis relation, the inappropriately augmented intrarenal ANG II content would contribute
to the pathogenesis of malignant hypertension in Cyp1a1-Ren2 transgenic rats.
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In summary, the present findings confirm that AT1 receptor activation contributes to the
increase in SBP and proteinuria in Cyp1a1-Ren2 transgenic rats with ANG II-dependent
malignant hypertension. These data also demonstrate that the urinary excretion of
angiotensinogen is markedly augmented in ANG II-dependent malignant hypertension. Such
increased urinary angiotensinogen excretion likely reflects an AT1 receptor-mediated
augmentation of intraluminal angiotensinogen levels which may contribute to augmented
intrarenal ANG II levels and, thereby, to the increased blood pressure in Cyp1a1-Ren2
transgenic rats with inducible ANG II-dependent malignant hypertension.
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FIG. 1.
Conscious systolic blood pressures of non-induced Cyp1a1-Ren2 rats (Non-induced); Cyp1a1-
Ren2 rats fed a normal-salt diet containing 0.3% I3C for 10 days (0.3% I3C); and Cyp1a1-
Ren2 rats induced for 10 days with 0.3% I3C and treated with the AT1 receptor antagonist,
candesartan (Cand; 25 mg/L in drinking water) (0.3% I3C+Cand). *P<0.05, **P<0.001 vs.
day 0.
Milani et al. Page 10
Am J Med Sci. Author manuscript; available in PMC 2011 November 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 2.
Body weights of non-induced Cyp1a1-Ren2 rats (Non-induced); Cyp1a1-Ren2 rats fed a
normal-salt diet containing 0.3% I3C for 10 days (0.3% I3C); and Cyp1a1-Ren2 rats induced
for 10 days with 0.3% I3C and treated with the AT1 receptor antagonist, candesartan (Cand;
25 mg/L in drinking water) (0.3% I3C+Cand). *P<0.001 vs. day 0.
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FIG. 3.
Effects of I3C, and I3C+Cand on urinary protein excretion in Cyp1a1-Ren2 transgenic rats.
*P<0.01, **P<0.001 vs. day -3.
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FIG. 4.
Effects of I3C, and I3C+Cand on urinary angiotensinogen excretion in Cyp1a1-Ren2
transgenic rats. *P<0.05, **P<0.01, ***P<0.001 vs. day -3.
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